$20.9BEquity raised in 2025–20262025 $8.4B · 2026 $12.6B · 3.1% of all tracked equity · plus $501M debt/secondary
40Companies59 equity rounds in 2025–2026
#8Rank by 2025–2026 equityof 12 sectors
$24.2BEquity raised, all timeall sourced equity rounds
Companies ranked by 2025–2026 equity
| # | Company | Equity 2025–2026 |
|---|---|---|
| 1 | Isomorphic Labs | $2.7B2025 $600M · 2026 $2.1B |
| 2 | MiRus | $1.5B2025 — · 2026 $1.5B |
| 3 | Parabilis Medicines | $975M2025 — · 2026 $975M |
| 4 | Neko Health | $960M2025 $260M · 2026 $700M |
| 5 | Oura | $900M2025 $900M · 2026 — |
| 6 | Earendil Labs | $787M2025 — · 2026 $787M |
| 7 | Eikon Therapeutics | $732M2025 $351M · 2026 $381M |
| 8 | OpenEvidence | $660M2025 $410M · 2026 $250M |
| 9 | Neuralink | $650M2025 $650M · 2026 — |
| 10 | Pathos AI | $602M2025 $365M · 2026 $237M |
| 11 | CMR Surgical | $600M2025 $200M · 2026 $400M |
| 12 | Kailera Therapeutics | $600M2025 $600M · 2026 — |
| 13 | Chai Discovery | $600M2025 $200M · 2026 $400M |
| 14 | NewLimit | $565M2025 $130M · 2026 $435M |
| 15 | Kardigan | $554M2025 $554M · 2026 — |
| 16 | Enveda | $461M2025 $150M · 2026 $311M |
| 17 | Ollin Biosciences | $430M2025 $100M · 2026 $330M |
| 18 | Beeline Medicines | $426M2025 — · 2026 $426M |
| 19 | Verdiva Bio | $411M2025 $411M · 2026 — |
| 20 | Tubulis | $401M2025 $401M · 2026 — |
| 21 | MapLight Therapeutics | $373M2025 $373M · 2026 — |
| 22 | Dren Bio | $350M2025 — · 2026 $350M |
| 23 | Cellares | $327M2025 — · 2026 $327M |
| 24 | Truveta | $320M2025 $320M · 2026 — |
| 25 | Kriya Therapeutics | $320M2025 $320M · 2026 — |
| 26 | AdvanCell | $315M2025 — · 2026 $315M |
| 27 | OMass Therapeutics | $310M2025 — · 2026 $310M |
| 28 | Function Health | $298M2025 $298M · 2026 — |
| 29 | Corxel | $287M2025 — · 2026 $287M |
| 30 | Encoded Therapeutics | $275M2025 — · 2026 $275M |
| 31 | LifeMine Therapeutics | $263M2025 — · 2026 $263M |
| 32 | AMBOSS | $259M2025 $259M · 2026 — |
| 33 | Judi Health | $252M2025 $252M · 2026 — |
| 34 | Anagram Therapeutics | $250M2025 — · 2026 $250M |
| 35 | Mirador Therapeutics | $250M2025 — · 2026 $250M |
| 36 | Precision Neuroscience | $250M2025 — · 2026 $250M |
| 37 | Oviva | $220M2025 — · 2026 $220M |
| 38 | Heidi Health | $182M2025 $81.6M · 2026 $100M+$240M debt |
| 39 | Innovaccer | $179M2025 $179M · 2026 —+$96M secondary |
| 40 | Beren Therapeutics | $135M2025 — · 2026 $135M+$165M debt |
Most active investors by companies backed
- T. Rowe Price8 companies
- GV7 companies · 4 led
- ARCH Venture Partners6 companies · 3 led
- General Catalyst6 companies · 2 led
- Fidelity6 companies · 2 led
- Thrive Capital5 companies · 4 led
- RA Capital Management5 companies · 1 led
- Dimension4 companies · 1 led
- Sequoia Capital4 companies · 1 led
- Sanofi4 companies · 1 led